Pharma

Explaining the Explosion in the Dry Eye Space

Explaining the Explosion in the Dry Eye Space

By Steve Lenier | November 14, 2018

At OIS@AAO 2018, strong attendance at the breakfast breakout session “Evolution of the Dry Eye Market” made a statement about the current level of interest…

Read More
Can Retina Candidates Find Their Place?

Where Can Emerging Retina Agents Find Their Place in Clinical Practice?

By Rich Kirkner | November 8, 2018

Few therapeutic areas in medicine have a drug pipeline as flush as retina’s, as shown by trial results of a dozen or more emerging therapies…

Read More
The Sweet Six: Recipients of the 2018 Ophthalmology Innovation Awards

The Sweet Six: Recipients of the 2018 Ophthalmology Innovation Awards

By Rich Kirkner | October 25, 2018

The first Ophthalmology Innovation Awards were presented last night at the OIS-X Gala. Here’s a rundown of the award winners. Clinical Innovator: Ike Ahmed, MD…

Read More
YUTIQ Approval Latest Step in EyePoint’s Transformation

YUTIQ Approval Latest Step in EyePoint’s Transformation

By Rich Kirkner | October 17, 2018

The steroidal implant YUTIQ for treatment of chronic, noninfectious posterior uveitis is the second drug in EyePoint Pharmaceuticals’ ophthalmology portfolio to receive Food and Drug…

Read More
First US-Approved Nerve Growth Factor is for the Eye

First US-Approved Nerve Growth Factor is for the Eye

By Rich Kirkner | August 24, 2018

In the use of biological agents for treatment of eye disease, the back of the eye has been pretty much the sole domain thanks to…

Read More
Novartis’ Plans for Brolucizumab and Beyond

Novartis’ Guerard Shares Plans for Brolucizumab, Lucentis, Gene Therapy, and FocalView App

By Rich Kirkner | August 22, 2018

Coming off the positive feedback at the American Society of Retina Specialists meeting to trial results of the investigative anti-VEGF agent brolucizumab, Frederic Guerard, Novartis’…

Read More
After Trial Results, Allergan Set to Tweak Abcipar Formulation

After Trial Results, Allergan Set to Tweak Abcipar Formulation

By Rich Kirkner | July 26, 2018

Last week, one day before the American Society of Retina Specialists and OIS Retina convened in Vancouver, Allergan and its collaborative partner Molecular Partners touted…

Read More
Ocular Therapeutix Revamps to Address FDA’s Dextenza Concerns

Ocular Therapeutix Revamps to Address FDA’s Dextenza Concerns

By Steve Lenier | July 18, 2018

When Ocular Therapeutix resubmitted its new drug application for Dextenza late in June, it represented a milestone in the company’s effort to essentially reshape itself…

Read More
FFB Showcase an OIS Retina Can’t-Miss

Here’s What You’ll Learn at OIS Retina’s Emerging Science Session

By Rich Kirkner | July 12, 2018

OIS Retina, set to kick off next Friday, July 20, when the annual meeting of the American Society of Retina Specialists (ASRS) starts in Vancouver,…

Read More
Anti-VEGF Biosimilars Target a Shifting Market

Anti-VEGF Biosimilars Target a Shifting Market

By Rich Kirkner | May 31, 2018

Developers of FYB201 may be getting a leg up in the race for a Lucentis biosimilar with the publication of interim results that confirm the…

Read More
How Badly Does Takeda Want Shire's Ophthalmology Franchise

How Badly Does Takeda Want Shire’s Ophthalmology Franchise?

By Rich Kirkner | May 16, 2018

Shire plc’s decision last week to accept the $62 billion acquisition offer by Takeda Pharmaceutical Company Ltd. has fed speculation in the pharma trade press…

Read More
A String of Pearls for Navigating the FDA

A String of Pearls for Navigating the FDA

By Steve Lenier | May 10, 2018

WASHINGTON, DC – Having OIS@ASCRS 2018 here provided the perfect opportunity for representatives of the US Food and Drug Administration to impart wisdom on how…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.